HeartBeam Inc BEAT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BEAT is a good fit for your portfolio.
News
-
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
-
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
-
First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG
-
HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
-
HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time
Trading Information
- Previous Close Price
- $2.04
- Day Range
- $2.00–2.07
- 52-Week Range
- $1.06–3.74
- Bid/Ask
- $2.05 / $2.17
- Market Cap
- $53.97 Mil
- Volume/Avg
- 13,855 / 134,594
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher-resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Growth
- Total Number of Employees
- 15
- Website
- https://www.heartbeam.com
Comparables
Valuation
|
Metric
|
BEAT
|
LFST
|
OPCH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 28.15 |
Price/Book Value | 3.30 | 1.64 | 3.64 |
Price/Sales | — | 2.15 | 1.21 |
Price/Cash Flow | — | 134.64 | 13.46 |
Price/Earnings
BEAT
LFST
OPCH
Financial Strength
|
Metric
|
BEAT
|
LFST
|
OPCH
|
|---|---|---|---|
Quick Ratio | 13.56 | 1.01 | 1.17 |
Current Ratio | 14.09 | 1.11 | 1.77 |
Interest Coverage | — | −8.74 | 8.00 |
Quick Ratio
BEAT
LFST
OPCH
Profitability
|
Metric
|
BEAT
|
LFST
|
OPCH
|
|---|---|---|---|
Return on Assets (Normalized) | −89.43% | −4.64% | 9.04% |
Return on Equity (Normalized) | −100.02% | −6.76% | 20.48% |
Return on Invested Capital (Normalized) | −105.93% | −4.11% | 12.73% |
Return on Assets
BEAT
LFST
OPCH
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Sdffdb | $39.4 Bil | |
VEEV
| Veeva Systems Inc Class A | Dxwrhzkh | Xvwxf | $32.4 Bil | |
SOLV
| Solventum Corp | — | Hfjnvsy | $11.0 Bil | |
MTHRF
| M3 Inc | — | Zyzbyyk | $8.3 Bil | |
MTHRY
| M3 Inc ADR | — | Yjzmgyr | $8.2 Bil | |
PMCUF
| Pro Medicus Ltd | — | Pggkmx | $7.2 Bil | |
HQY
| HealthEquity Inc | — | Vpzmpr | $6.8 Bil | |
RCM
| R1 RCM Inc | — | Frtj | $5.0 Bil | |
DOCS
| Doximity Inc Class A | — | Hgjyf | $4.5 Bil | |
EVH
| Evolent Health Inc Class A | — | Ylkk | $3.3 Bil |